evogliptin

Trade name: Suganon

Small moleculeexperimental

Evogliptin is an antidiabetic drug in the dipeptidyl peptidase-4 (DPP-4) inhibitor or "gliptin" class of drugs. It was developed by the South Korean pharmaceutical company Dong-A ST and is approved for use in South Korea and Russia. In a meta-analysis involving data from 6 randomized controlled trials, Dutta et. al. demonstrated the good glycaemic efficacy and safety of this medicine as compared to other DPP4 inhibitors like sitagliptin and linagliptin. — Wikipedia

Chemistry & pharmacology

Loading structure…

SMILES

CC(C)(C)OC[C@@H]1C(=O)NCCN1C(=O)C[C@H](N)Cc1cc(F)c(F)cc1F
Mol. weight
401.43 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Oral

Oral

Yes

Parenteral

No

Topical

No

Sources

Also known as

  • 4-(3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(tert-butoxymethyl)piperazin-2-one
  • da1229
  • da 1229
  • da-1229
  • da-1229
  • da-1229
  • evogliptin
  • evogliptin
  • evogliptin
  • evogliptin
  • evogliptin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07297940Phase 1Dec 31, 2025Dong-A Pharmaceutical
NCT05739916Phase 1Mar 30, 2023Dong-A Pharmaceutical
NCT05739903Phase 1Mar 25, 2023Dong-A Pharmaceutical
NCT05739851Phase 1Mar 18, 2023Dong-A Pharmaceutical
NCT05739877Phase 1Mar 17, 2023Dong-A Pharmaceutical
NCT05143177Phase 2/Phase 3 (Phase 3)Dec 1, 2021Mayo Clinic, REDNVIA
NCT04706637Phase 4Feb 1, 2021Dong-A Pharmaceutical, Kyung Hee University
NCT04653779Phase 4Dec 31, 2020Dong-A Pharmaceutical
NCT04521452Phase 4Sep 30, 2020REDNVIA, University of Ulsan
NCT05473806Phase 4Sep 18, 2020Yonsei University
NCT04356742Phase 3Apr 30, 2020Dong-A Pharmaceutical
NCT04195919Phase 1Dec 20, 2019Dong-A Pharmaceutical
NCT04170998Phase 3Nov 14, 2019Dong-A Pharmaceutical
NCT04055883Phase 2Aug 22, 2019Dong-A Pharmaceutical
NCT03910361Phase 4Apr 12, 2019Dong-A Pharmaceutical, Yonsei University
NCT03766724Phase 1Nov 22, 2018Dong-A Pharmaceutical, Yonsei University
NCT03667300Phase 2Mar 16, 2017Sungkyunkwan University
NCT02689362Phase 2Mar 1, 2017Eurofarma Laboratorios S.A.
NCT02954822Phase 1Nov 1, 2016Dong-A Pharmaceutical
NCT02974504Phase 4Sep 1, 2016Dong-A Pharmaceutical
Showing 20 of 31 trials
Page 1 / 2

Organizations

Research & Development (12)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Dong-A PharmaceuticalFor profit252442009
Yonsei UniversityAcademic/Hospital3122018
REDNVIAFor profit2122020
Seoul National UniversityAcademic/Hospital2012014
Dongguk UniversityAcademic/Hospital1112016
Eurofarma Laboratorios S.A.For profit1112017
Hallym UniversityAcademic/Hospital1012013
Kangbuk Samsung HospitalAcademic/Hospital1012013
Kyung Hee UniversityAcademic/Hospital1112021
Mayo ClinicAcademic/Hospital1012021
Sungkyunkwan UniversityAcademic/Hospital1112017
University of UlsanAcademic/Hospital1112020
12 organizations
Page 1 / 1